Research findings indicate that suppressing HIF−1α—through pharmacologic or genetic means—can eliminate immune evasion mediated by PD−L1, by reducing its expression on tumor−associated macrophages (TAMs) and malignant cells, which in turn triggers reactivation of tumor−infiltrating lymphocytes (TILs) and leads to tumor rejection (60). This evidence concerns the gene HIF1A and neoplasm.